Anti-OPGL [9H7]
Catalogue Number: AB04111-10.0-BT-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 1 mg |
| Host name: | Human |
| Clone: | 9H7 |
| Isotype: | IgG1 |
| Immunogen: | The original antibody was generated by immunizing transgenic HuMab mice with purified recombinant OPGL derived from E. coli or CHO cells. Sera from immunized mice were tested for antibody binding to OPGL. |
| Application: | ELISA, NT, InVivoA, SPR |
Additional Text
Gene ID
8600
Gene Name
TNFSF11
Uniprot ID
O14788
Purification
Purified
Antibody Clonality
Recombinant Monoclonal
Specificity
CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B
Storage Note
Store at 4⁰C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommed this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20⁰C.
Application Notes
The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a KD of 0.193 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC50 of 129 ng/ml. This antibody's pharmacokinetics and in vivo activity were assessed in cynomolgus monkeys. The antibody's levels in the serum declined slowly over the testing period; the last detectable measurement on day 49 showed a serum concentration of ~100 ng/ml. serum N-telopeptide (serum N-Tx) levels were greatly reduced compared to baseline immediately following injection (~minus 45%), further decreased to ~minus 75% over four days, and remained stable for a period of two weeks, after which they began to gradually increase until no longer lower than baseline in a statistically significant manner between day 35 to 42 (US7718776B2).
AB04111-10.0-BT Datasheet
SUPPORT
outstanding technical support
PRODUCT
we offer a full product guarantee
DELIVERY
we offer free delivery to UK universities and non profit organisations